Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2001 Sep;71(3):352-6.
doi: 10.1136/jnnp.71.3.352.

Epidemiology of seropositive myasthenia gravis in Greece

Affiliations

Epidemiology of seropositive myasthenia gravis in Greece

K Poulas et al. J Neurol Neurosurg Psychiatry. 2001 Sep.

Abstract

Objectives: To study the epidemiological characteristics of myasthenia gravis in Greece.

Methods: A population based study was carried out of seropositive myasthenia gravis in Greece for the period from 1 January 1983 to 30 June 1997; 843 patients were studied.

Results: The average annual incidence for the period 1992-7, for which the database is complete, was 7.40/million population/year (women 7.14; men 7.66). On 1 July 1997, there were 740 prevalent cases. The point prevalence rate was 70.63/million (women 81.58; men 59.39). The average overall annual mortality rate in the patients was 0.67/million population (women 0.53; men 0.82), and the mortality rate attributed to myasthenia gravis was 0.43/million population (women 0.41; men 0.45). The average age at onset was 46.50 years (women 40.16; men 54.46), and the mean age of the prevalent patients was 52.58 (women 47.65; men 59.48). The women:men incidence ratio was 1:1.04, and the prevalence ratio was 1.41:1. It is predicted that the prevalence and women: men prevalence ratio would increase if the patient list included all patients with a date of onset before 1983.

Conclusions: The largest epidemiological study ever performed on myasthenia gravis is presented. The most important epidemiological indexes are provided.

PubMed Disclaimer

References

    1. Neurology. 2000 Mar 14;54(5):1202-3 - PubMed
    1. Br Med J. 1956 Jun 2;1(4978):1259-62 - PubMed
    1. Ann N Y Acad Sci. 1966 Jan 26;135(1):431-5 - PubMed
    1. Acta Neurol Scand. 1977 Nov;56(5):365-88 - PubMed
    1. Methods Enzymol. 1981;74 Pt C:432-60 - PubMed

Publication types

MeSH terms